Pressure Ulcer Therapeutics Pipeline Insight – 2018 Size, Share, Industry, Forecast and outlook (2024-2031) Market -
PRESSURE ULCER THERAPEUTICS PIPELINE ANALYSIS
• Pressure ulcers are considered as an injury that is caused by breaking down the skin and underlying tissue. The body parts that are at higher risk of occurring pressure ulcers are those that are not covered by a large amount of body fat and are in direct contact with a supporting surface (bed or a wheelchair). Causes include continuous pressure, friction, and shear.
• Treatment includes antibiotics and nutrition. This causes cessation of nutrition and oxygen supply to the tissues, tissue necrosis, and tissue ischemia.
• The increased pressure will cause microcirculatory occlusion, and further leads to tissue death and ulceration. Pressure ulcers, also known to be bedsores or decubitus ulcers, which are often seen in geriatric people and hospital patients. It commonly occurs in acute respiratory patients and in the patients who spend in the bed for a longer period of time.
• As interface pressure is known to be the key risk factor in the pressure ulcers development, continuous visual feedback of continuous pressure imaging (CPI) between the body and support surface could inform healthcare providers on repositioning strategies and play an important role in an overall strategy for the management and prevention of pressure ulcers.
• High unmet needs found in the global pressure ulcers treatment market is going to create more opportunities for existing players and also for the new entrants.
• Recent studies that are conducted on pressure ulcers include: a) a Pressure Ulcer-Associated Osteomyelitis: by evaluating Two-Stage Surgical Strategy along with Prolonged Antimicrobial Therapy by Hospices Civils De Lyon, France, b) Subcutaneous Injection and Ultrasonic Dispersion Of Cefazolin Into Chronic Pelvic-Region Pressure Ulcers In Persons With Spinal Cord Injury by James J. Peters Veterans Affairs Medical Center, c) Changes in Bacterial Flora among patients with Pelvic Bedsores: by a Prospective Pilot Study of Escaflor by Centre Hospitalier Universitaire De N?mes, Inc., and d) Puraply Antimicrobial Wound Matrix and Wound Management (puraplyam) by Organogenesis.
• Less number of studies is found to be in clinical phase trial developmental stages. Among which, 8 studies are found in phase III stage of development including PRP Concepts Fibrin Bio-Matrix to treat pressure ulcers by PRP Concepts, LLC. And the drugs that come in this pipeline include Ketamine, Midazolam, Liposomal Bupivacaine, Epinephrine, Hyperbaric oxygen, Quadratus Lumborum Block (QLB). James J. Peters Veterans Affairs Medical Center is in the process of developing pioglitazone as a peroxisome proliferator-activated receptor gamma (PPAR?) agonist for the treatment of pressure ulcers.
• Fundaci?n Cardioinfantil Instituto de Cardiolog?a is also in the process of developing skin dressing for the treatment of pressure ulcer. Aurix is a platelet-rich plasma gel used in the treatment of non-healing chronic wounds. The results of Aurix to date when used to treat Pressure ulcers have been promising.
• The rise in adoption of artificial skin substitutes and an increase in the number of patients with pressure ulcers are going to fuel the growth of the market.
• However, the increasing demand for pressure ulcers treatment products projected to decline during the forecast period leading to high cost of advanced wound care products and also leading to unfavorable reimbursement policies.
• The pressure ulcers market is driven by an increase in the geriatric population increase in the number of pressure ulcers cases among the geriatric population, and surge in demand for dressings, devices, and sealants.
• The growth of the wound care dressings segment is primarily driven by usage of antimicrobial dressings for treatment of pressure ulcers.
• Pressure ulcers are considered as an injury that is caused by breaking down the skin and underlying tissue. The body parts that are at higher risk of occurring pressure ulcers are those that are not covered by a large amount of body fat and are in direct contact with a supporting surface (bed or a wheelchair). Causes include continuous pressure, friction, and shear.
• Treatment includes antibiotics and nutrition. This causes cessation of nutrition and oxygen supply to the tissues, tissue necrosis, and tissue ischemia.
• The increased pressure will cause microcirculatory occlusion, and further leads to tissue death and ulceration. Pressure ulcers, also known to be bedsores or decubitus ulcers, which are often seen in geriatric people and hospital patients. It commonly occurs in acute respiratory patients and in the patients who spend in the bed for a longer period of time.
• As interface pressure is known to be the key risk factor in the pressure ulcers development, continuous visual feedback of continuous pressure imaging (CPI) between the body and support surface could inform healthcare providers on repositioning strategies and play an important role in an overall strategy for the management and prevention of pressure ulcers.
• High unmet needs found in the global pressure ulcers treatment market is going to create more opportunities for existing players and also for the new entrants.
• Recent studies that are conducted on pressure ulcers include: a) a Pressure Ulcer-Associated Osteomyelitis: by evaluating Two-Stage Surgical Strategy along with Prolonged Antimicrobial Therapy by Hospices Civils De Lyon, France, b) Subcutaneous Injection and Ultrasonic Dispersion Of Cefazolin Into Chronic Pelvic-Region Pressure Ulcers In Persons With Spinal Cord Injury by James J. Peters Veterans Affairs Medical Center, c) Changes in Bacterial Flora among patients with Pelvic Bedsores: by a Prospective Pilot Study of Escaflor by Centre Hospitalier Universitaire De N?mes, Inc., and d) Puraply Antimicrobial Wound Matrix and Wound Management (puraplyam) by Organogenesis.
• Less number of studies is found to be in clinical phase trial developmental stages. Among which, 8 studies are found in phase III stage of development including PRP Concepts Fibrin Bio-Matrix to treat pressure ulcers by PRP Concepts, LLC. And the drugs that come in this pipeline include Ketamine, Midazolam, Liposomal Bupivacaine, Epinephrine, Hyperbaric oxygen, Quadratus Lumborum Block (QLB). James J. Peters Veterans Affairs Medical Center is in the process of developing pioglitazone as a peroxisome proliferator-activated receptor gamma (PPAR?) agonist for the treatment of pressure ulcers.
• Fundaci?n Cardioinfantil Instituto de Cardiolog?a is also in the process of developing skin dressing for the treatment of pressure ulcer. Aurix is a platelet-rich plasma gel used in the treatment of non-healing chronic wounds. The results of Aurix to date when used to treat Pressure ulcers have been promising.
• The rise in adoption of artificial skin substitutes and an increase in the number of patients with pressure ulcers are going to fuel the growth of the market.
• However, the increasing demand for pressure ulcers treatment products projected to decline during the forecast period leading to high cost of advanced wound care products and also leading to unfavorable reimbursement policies.
• The pressure ulcers market is driven by an increase in the geriatric population increase in the number of pressure ulcers cases among the geriatric population, and surge in demand for dressings, devices, and sealants.
• The growth of the wound care dressings segment is primarily driven by usage of antimicrobial dressings for treatment of pressure ulcers.
